Transgene Biotek (526139)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Small market cap of ₹77 Cr gives room for a meaningful re-rating if the business ever generates revenue.
• Price of ₹9.56 is at the top of the 52-week range (₹1.83–₹9.56), showing current market enthusiasm.
• Healthcare services exposure offers long-term Indian demographic tailwinds, if the company can execute.
• Headline ROE of 28.30% is a tempting surface positive, though contradicted by loss-making operations.

Concerns

• Latest quarter sales are ₹0 Cr with a net loss of ₹-0 Cr, so the company has no current earnings power; P/E is 0.
• Sales growth is -37.50% and profit growth -311.11%, indicating severe deterioration.
• Piotroski F-Score of 2/9 and ROCE of -1.75% point to weak financial health and poor capital allocation.
• No dividend and unavailable book value/promoter holding/debt-equity data leave no margin-of-safety anchor.

AI Analysis

Let me begin with a confession: This is exactly the kind of stock I would normally toss into the 'too hard' pile. Transgene Biotek has a market cap of ₹77 crore at ₹9.56 per share, but what does the business actually earn? The latest quarter shows sales of ₹0 crore and a net profit of ₹-0 crore. Full-year momentum is worse: sales fell 37.5%, and profit growth was minus 311%. A Piotroski F-score of 2 out of 9 is a red flag—it tells me the financial health is deteriorating, not improving. ROCE is -1.75%, so the company isn't earning a decent return on capital. The headline ROE of 28.30% might tempt a naive investor, but with zero revenue and losses, I consider it an accounting mirage. There is no dividend, so I get no cash while I wait. The price has run from ₹1.83 to ₹9.56, but a rising share price without rising earnings is just sentiment. Graham would ask: Where is the margin of safety? Book value, promoter holding, and debt/equity are unavailable, so I cannot calculate asset backing. This isn't value investing; it's speculation. For a healthcare service provider, India's long-term demand is real, but this particular company must first prove it can generate sales. I can only revisit if sustainable revenue reappears, profits turn positive, and the balance sheet is disclosed. Until then, I remain on the sidelines. Capital preservation comes before potential—and here, there is too little to preserve.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer